Prostate-Derived ETS Factor (PDEF) Modulates Yes Associated Protein 1 (YAP1) in Prostate Cancer Cells: A Potential Cross-Talk between PDEF and Hippo Signaling

被引:4
|
作者
Jaiswal, Praveen Kumar [1 ,3 ]
Mohajan, Suman [1 ]
Koul, Sweaty [2 ,3 ]
Wang, Fengtian [1 ]
Shi, Runhua [3 ]
Koul, Hari K. [1 ,3 ]
机构
[1] LSU Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA
[2] LSU Hlth Sci Ctr, Dept Urol, Shreveport, LA 71130 USA
[3] LSU Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA
关键词
YAP1; PDEF; prostate cancer; CASTRATION-RESISTANT GROWTH; SIZE-CONTROL; PATHWAY; TAZ; EXPRESSION; ANTIANDROGEN; HOMEOSTASIS; CONTRIBUTE; INVASION; BREAST;
D O I
10.3390/ph12040181
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
PDEF (prostate-derived ETS factor, also known as SAM-pointed domain containing ETS transcription factor (SPDEF)) is expressed in luminal epithelial cells of the prostate gland and associates with luminal phenotype. The Hippo pathway regulates cell growth/proliferation, cellular homeostasis, and organ development by modulating phosphorylation of its downstream effectors. In previous studies, we observed decreased levels of PDEF during prostate cancer progression. In the present study, we evaluated the effects of the expression of PDEF on total/phosphoprotein levels of YAP1 (a downstream effector of the Hippo pathway). We observed that the PC3 and DU145 cells transfected with PDEF (PDEF-PC3 and PDEF-DU145) showed an increased phospho-YAP1 (Ser127) and total YAP1 levels as compared to the respective PC3 vector control (VC-PC3) and DU145 vector control cells (VC-DU145). We also observed an increased cytoplasmic YAP1 levels in PDEF-PC3 cells as compared to VC-PC3 cells. Moreover, our gene set enrichment analysis (GSEA) of mRNA expression in PDEF-PC3 and VC-PC3 cells revealed that PDEF resulted in inhibition of YAP1 target genes, directly demonstrating that PDEF plays a critical role in modulating YAP1 activity, and by extension in the regulation of the Hippo pathway. We also observed a decrease in YAP1 mRNA levels in prostate cancer tissues as compared to normal prostate tissues. Our analysis of multiple publicly available clinical cohorts revealed a gradual decrease in YAP1 mRNA expression during prostate cancer progression and metastasis. This decrease was similar to the decrease in PDEF levels, which we had reported earlier, and we observed a direct correlation between PDEF and YAP1 expression in CRPC data set. To the best of our knowledge, these results provide the first demonstration of inhibiting YAP1 activity by PDEF in any system and suggest a cross-talk between PDEF and the Hippo signaling pathway.
引用
收藏
页数:11
相关论文
共 21 条
  • [1] Prostate-Derived Ets Transcription Factor (PDEF) Is a Potential Prognostic Marker in Patients With Prostate Cancer
    Ghadersohi, Ali
    Sharma, Satish
    Zhang, Shaozeng
    Azrak, Rami G.
    Wilding, Gregory E.
    Manjili, Masoud H.
    Li, Fengzhi
    [J]. PROSTATE, 2011, 71 (11): : 1178 - 1188
  • [2] Retraction Note to: Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF
    Thomas R. Johnson
    Sweaty Koul
    Binod Kumar
    Lakshmipathi Khandrika
    Sarah Venezia
    Paul D. Maroni
    Randall B. Meacham
    Hari K. Koul
    [J]. Molecular Cancer, 20
  • [3] RETRACTED ARTICLE: Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF
    Thomas R Johnson
    Sweaty Koul
    Binod Kumar
    Lakshmipathi Khandrika
    Sarah Venezia
    Paul D Maroni
    Randall B Meacham
    Hari K Koul
    [J]. Molecular Cancer, 9
  • [4] RETRACTED: Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF (Retracted Article)
    Johnson, Thomas R.
    Koul, Sweaty
    Kumar, Binod
    Khandrika, Lakshmipathi
    Venezia, Sarah
    Maroni, Paul D.
    Meacham, Randall B.
    Koul, Hari K.
    [J]. MOLECULAR CANCER, 2010, 9
  • [5] Prostate-Derived Ets Factor (PDEF) Inhibits Metastasis by Inducing Epithelial/Luminal Phenotype in Prostate Cancer Cells
    Wang, Fengtian
    Koul, Sweaty
    Shanmugam, Prakash S. T.
    Dong, Qin
    Koul, Hari K.
    [J]. MOLECULAR CANCER RESEARCH, 2018, 16 (09) : 1430 - 1440
  • [6] RETRACTION: Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF (Retraction of Vol 9, art no 148, 2010)
    Johnson, Thomas R.
    Koul, Sweaty
    Kumar, Binod
    Khandrika, Lakshmipathi
    Venezia, Sarah
    Maroni, Paul D.
    Meacham, Randall B.
    Koul, Hari K.
    [J]. MOLECULAR CANCER, 2021, 20 (01)
  • [7] Cross-talk between BRAF and Hippo/YAP1 signaling in melanoma
    Raj, Mohan Kumar Durai
    Nguyen, Jonathan
    Bora-Singhal, Namrata
    Messina, Jane
    Gibney, Geoffrey
    Chellappan, Srikumar
    [J]. CANCER RESEARCH, 2017, 77
  • [8] Over-expression of WW domain containing transcription regulator 1 (TAZ/WWTR1) in prostate cancer and its modulation by prostate-derived ETS factor (PDEF)
    Jaiswal, Praveen K.
    Mohajan, Suman
    Koul, Sweaty
    Koul, Hari K.
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [9] ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells
    Machado-Neto, Joao Agostinho
    Lazarini, Mariana
    Favaro, Patricia
    Franchi, Gilberto Carlos, Jr.
    Nowill, Alexandre Eduardo
    Olalla Saad, Sara Teresinha
    Traina, Fabiola
    [J]. EXPERIMENTAL CELL RESEARCH, 2014, 324 (02) : 137 - 145
  • [10] Cross-talk between alpha1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation
    Maria Beatrice Morelli
    Consuelo Amantini
    Massimo Nabissi
    Sonia Liberati
    Claudio Cardinali
    Valerio Farfariello
    Daniele Tomassoni
    Wilma Quaglia
    Alessandro Piergentili
    Alessandro Bonifazi
    Fabio Del Bello
    Matteo Santoni
    Gabriele Mammana
    Lucilla Servi
    Alessandra Filosa
    Angela Gismondi
    Giorgio Santoni
    [J]. BMC Cancer, 14